Levels of inflammatory markers. ????? ?????? ?? ?????? ????
Conditions
Interventions
Intervention 1: Intervention group: atrovastetin is a drug manufactured by Abidi Pharmaceutical Company at a dose of 80 mg once daily after dinner for 60 days. Intervention 2: Intervention group: Rosv
Sponsors
Neyshabour University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Acute coronary syndrome based on clinical signs and ECG and serum markers
Exclusion criteria
Exclusion criteria: renal failure Liver failure Immunosuppressants, corticosteroids or potent inhibitors of cytochrome P450 3A4, pentoxifylline, silostazole, glucosamine, berberine barberry extract Having underlying inflammatory or infectious diseases Left Schiff's Leukostosis TG>400 CHF with NYHA III or IV Having a history of diseases that cause malabsorption syndromes Uncontrolled blood pressure Evidence of endocrine or metabolic disease affecting lipid profile
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood levels of inflammatory markers. Timepoint: Before starting the study and 60 days later beginning. Method of measurement: Laboratory measurement by ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: Before the intervention and at the end of the intervention. Method of measurement: Laboratory measurement with Pars test kit with Autoanalyzer bt 3000.;Blood levels of inflammatory markers. Timepoint: Before the intervention and at the end of the intervention. Method of measurement: Laboratory tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyedeh Samaneh Tabaee
Neyshabour University of Medical Sciences
Outcome results
None listed